← Eichor
Condition: Neurotrophic Keratitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neurotrophic Keratitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune D
Phase 4 · 1 location(s) · Toyos Clinic · NCT06964269The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
Phase N/A · 1 location(s) · Indiana University · NCT04700657Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06919081Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic
Phase 4 · 1 location(s) · University of South Florida · NCT07502378An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
Phase 3 · 77 location(s) · Dompé Farmaceutici S.p.A · NCT07519902Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Phase 2 · 1 location(s) · BRIM Biotechnology Inc. · NCT05927428Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology
Phase N/A · 1 location(s) · Neuro-Ophthalmology of Texas · NCT07566975Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
NA · 1 location(s) · Universidad Autonoma de Nuevo Leon · NCT04604834Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Phase 3 · 36 location(s) · ReGenTree, LLC · NCT05555589A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of
Phase 2 · 3 location(s) · TearSolutions, Inc. · NCT07568730A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
Phase 1/Phase 2 · 9 location(s) · Krystal Biotech, Inc. · NCT06999733A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Phase 2 · 1 location(s) · Staidson (Beijing) Biopharmaceuticals Co., Ltd · NCT06975748
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.